{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"A responder was assessed as having CR or PR. CR: ≤ 5% myeloblasts with normal maturation of all cell lines and return to normal cellularity; osteomyelofibrosis was absent or equal to mild reticulin fibrosis; resolution of extramedullary disease present before therapy.\n\nPR: normalization of peripheral counts and hepatosplenomegaly with bone marrow blasts reduced by 50% but \\>5% of cellularity except in cases of MDS/MPN with ≤ 5% blasts at baseline.","groups":[{"description":"Participants received IV AMG 176 at dose level 1 once a week in 28-day cycles. Treatment was planned until disease progression or unacceptable toxicity.","id":"OG000","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1"},{"description":"Participants received IV AMG 176 at dose level 1 on cycle 1 day 1 and then dose level 2 from cycle 1 day 8 and once a week thereafter (each cycle = 28 days). Treatment was planned until disease progression or unacceptable toxicity.","id":"OG001","title":"Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 2"}],"populationDescription":"The full analysis set included all enrolled participants who received at least 1 dose of AMG 176. No participants were responders.","reportingStatus":"POSTED","timeFrame":"Cycle 1 to disease progression or end of study, whichever occurred earlier (cycle length = 28 days). Median time on study was 4.1 months","title":"Duration of Response According to the Uniform Response Criteria for MDS/MPN","type":"SECONDARY"}